Wuhan Zhongyuan Ruide Biological Products

Wuhan Zhongyuan Ruide Biological Products is a leading Chinese biopharmaceutical company specializing in the development and manufacture of plasma-derived therapies. Founded in 1995 and headquartered in Wuhan, the company produces a critical portfolio of blood products, including human albumin, intravenous immunoglobulins (IVIG), and coagulation factors. In 2017, the company was acquired by CSL Behring, a global leader in the plasma protein biotherapeutics industry, to serve as a strategic hub for its operations in the Chinese market. Zhongyuan Ruide operates advanced manufacturing facilities and a network of plasma collection centers across China, adhering to international quality standards. The company's products are essential for treating patients with rare diseases, immune deficiencies, and life-threatening conditions such as hemophilia.